Page last updated: 2024-12-11

phenylahistin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

phenylahistin: antineoplastic from Aspergillus ustus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9798496
CHEMBL ID319291
SCHEMBL ID81222
MeSH IDM0305583

Synonyms (9)

Synonym
(-)-phenylahistin
CHEMBL319291
phenylahistin
SCHEMBL81222
200815-37-8
(3s,6z)-3-benzyl-6-[[5-(2-methylbut-3-en-2-yl)-1h-imidazol-4-yl]methylidene]piperazine-2,5-dione
GWMHBVLPNWHWGW-CNYBTUBUSA-N
Q15425275
DTXSID801336373

Research Excerpts

Overview

Phenylahistin is a fungal diketopiperazine derived from isoprenylated (Phe-DeltaHis) cyclodipeptide. It is a new cell cycle inhibitor produced by Aspergillus ustus.

ExcerptReferenceRelevance
"Phenylahistin is a fungal diketopiperazine derived from isoprenylated (Phe-DeltaHis) cyclodipeptide. "( Metabolism of phenylahistin enantiomers by cytochromes P450: a possible explanation for their different cytotoxicity.
Abadie, C; André, F; Aninat, C; Delaforge, M; Hamon, V; Hayashi, Y; Heyd, B; Perrin, L, 2008
)
2.15
"Phenylahistin is a new cell cycle inhibitor produced by Aspergillus ustus. "( Antitumor activity of phenylahistin in vitro and in vivo.
Hayashi, Y; Kanoh, K; Katada, J; Kohno, S; Muramatsu, M; Uno, I, 1999
)
2.06

Toxicity

ExcerptReferenceRelevance
" (-)-Phenylahistin proved to be less toxic on P450-rich hepatocytes than on P450-deprived KB lines."( Metabolism of phenylahistin enantiomers by cytochromes P450: a possible explanation for their different cytotoxicity.
Abadie, C; André, F; Aninat, C; Delaforge, M; Hamon, V; Hayashi, Y; Heyd, B; Perrin, L, 2008
)
1.22
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1587854Antiproliferative activity against human MCF cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2019European journal of medicinal chemistry, Jun-01, Volume: 171Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
AID1587851Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2019European journal of medicinal chemistry, Jun-01, Volume: 171Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
AID1587856Antiproliferative activity against mouse P388 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2019European journal of medicinal chemistry, Jun-01, Volume: 171Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
AID1587853Antiproliferative activity against human K562 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2019European journal of medicinal chemistry, Jun-01, Volume: 171Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
AID1587852Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2019European journal of medicinal chemistry, Jun-01, Volume: 171Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
AID1587855Antiproliferative activity against human WiDr cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2019European journal of medicinal chemistry, Jun-01, Volume: 171Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
AID628581Cytotoxicity against human HT-29 cells2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Highlights of marine invertebrate-derived biosynthetic products: their biomedical potential and possible production by microbial associants.
AID1587850Antiproliferative activity against human A432 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2019European journal of medicinal chemistry, Jun-01, Volume: 171Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (27.27)18.2507
2000's3 (27.27)29.6817
2010's5 (45.45)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.47 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (27.27%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (72.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]